The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: There are no known effective treatments for painful chemotherapy-induced peripheral neuropathy. OBJECTIVE: To determine the effect of duloxetine, 60 mg daily, on average pain severity. DESIGN, SETTING, AND PATIENTS: Randomized, double-blind, placebo-controlled crossover trial at 8 National Cancer Institute (NCI)-funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment. INTERVENTIONS: The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks. MAIN OUTCOME MEASURES: The primary hypothesis was that duloxetine would be more effective than placebo in decreasing chemotherapy-induced peripheral neuropathic pain. Pain severity was assessed using the Brief Pain Inventory-Short Form "average pain" item with 0 representing no pain and 10 representing as bad as can be imagined. RESULTS: Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513). The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20). Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount. CONCLUSION AND RELEVANCE: Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00489411.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,421
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471 · cited 1×
“Stratification factors Neurotoxic agent Paclitaxel 44 (40) 43 (39) 87 (40)”
BackgroundValidation of the Brief Pain Inventory for chronic nonmalignant pain
Tan, G., Jensen, M. P., Thornby, J. I., & Shanti, B. F. (2004) · The Journal of Pain · doi:10.1016/j.jpain.2003.12.005 · Cited by 1,416 · cited 6×
“The BPI-SF worse pain severity item has been shown to be reliable and valid for use as a single item.20 However, we chose average pain severity as our primary outcome measure based on recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT).21 In addition, average p…”
MethodInfluentialDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Neuroanatomy of the pain system and of the pathways that modulate pain
Willis, W. D., & Westlund, K. N. (1997) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199701000-00002 · Cited by 924
Duloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858
Cella, D., Eton, D. T., Lai, J.-S., Peterman, A. H., & Merkel, D. E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00529-8 · Cited by 808
Antidepressants for neuropathic pain
Saarto, T., & Wiffen, P. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005454.pub2 · Cited by 764
The Brief Pain Inventory User Guide
Cleeland, C. S. (2009) · Cited by 716
Dworkin, R. H., Turk, D. C., McDermott, M. P., Peirce-Sandner, S., Burke, L. B., Cowan, P., Farrar, J. T., Hertz, S., Raja, S. N., Rappaport, B. A., et al. (2009) · Pain · doi:10.1016/j.pain.2009.08.019 · Cited by 654
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Raskin, J., Pritchett, Y. L., Wang, F., D'Souza, D. N., Waninger, A. L., Iyengar, S., & Wernicke, J. F. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00061.x · Cited by 532
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y. L., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 510
Calhoun, E. A., Welshman, E. E., Chang, C.-H., Lurain, J. R., Fishman, D. A., Hunt, T. L., & Cella, D. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13603.x · Cited by 392
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Baron, R., Bellamy, N., Burke, L. B., Chappell, A., Chartier, K., Cleeland, C. S., Costello, A., et al. (2010) · Pain · doi:10.1016/j.pain.2010.02.018 · Cited by 381 · cited 3×
“A10%to20%decrease inpainseverity isconsideredtorepresent aminimal clinically important change, a 30%changerepresentsamoderately important improvement and a 50% change represents a substantially important improvement.(21,39,48)Duringinitialtreatment, themeanchangeinaveragepainscorereportedbypatientstreatedwithduloxetin…”
BackgroundMethodInfluentialCELLA, D., ETON, D., FAIRCLOUGH, D., BONOMI, P., HEYES, A., SILBERMAN, C., WOLF, M., & JOHNSON, D. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00477-2 · Cited by 380
Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
Rao, R. D., Michalak, J. C., Sloan, J. A., Loprinzi, C. L., Soori, G. S., Nikcevich, D. A., Warner, D. O., Novotny, P., Kutteh, L. A., Wong, G. Y., et al. (2007) · Cancer · doi:10.1002/cncr.23008 · Cited by 360
Chappell, A. S., Ossanna, M. J., Liu-Seifert, H., Iyengar, S., Skljarevski, V., Li, L. C., Bennett, R. M., & Collins, H. (2009) · Pain · doi:10.1016/j.pain.2009.06.024 · Cited by 294
The effect of symptom clusters on functional status and quality of life in women with breast cancer
Dodd, M. J., Cho, M. H., Cooper, B. A., & Miaskowski, C. (2010) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2009.09.005 · Cited by 290
Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1
Loprinzi, C. L., Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le-Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0308 · Cited by 281
Self-citationCavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., & Bidoli, P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.008 · Cited by 274
NCCN Task Force Report: Management of Neuropathy in Cancer
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., Junck, L., Morris, G. S., Paice, J. A., Tummala, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0078 · Cited by 257
Barton, D. L., Wos, E. J., Qin, R., Mattar, B. I., Green, N. B., Lanier, K. S., Bearden, J. D., Kugler, J. W., Hoff, K. L., Reddy, P. S., et al. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-010-0911-0 · Cited by 255
Hammack, J. E., Michalak, J. C., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Soori, G. S., Tirona, M. T., Rowland, K. M., Stella, P. J., & Johnson, J. A. (2002) · Pain · doi:10.1016/s0304-3959(02)00047-7 · Cited by 231
Atkinson, T. M., Mendoza, T. R., Sit, L., Passik, S., Scher, H. I., Cleeland, C., & Basch, E. (2010) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00774.x · Cited by 224
Chappell, A. S., Desaiah, D., Liu‐Seifert, H., Zhang, S., Skljarevski, V., Belenkov, Y., & Brown, J. P. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00401.x · Cited by 221
Background Noise: The Experience of Chemotherapy-Induced Peripheral Neuropathy
Bakitas, M. A. (2007) · Nursing Research · doi:10.1097/01.nnr.0000289503.22414.79 · Cited by 212
HUANG, H. Q., BRADY, M. F., CELLA, D., & FLEMING, G. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00794.x · Cited by 209
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy
Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., & Aaronson, N. K. (1998) · Annals of Oncology · doi:10.1023/a:1008344507482 · Cited by 207
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
Skinner, M. H., Kuan, H., Pan, A., Sathirakul, K., Knadler, M. P., Gonzales, C. R., Yeo, K. P., Reddy, S., Lim, M., Ayan‐Oshodi, M., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.28 · Cited by 195
Rao, R. D., Flynn, P. J., Sloan, J. A., Wong, G. Y., Novotny, P., Johnson, D. B., Gross, H. M., Renno, S. I., Nashawaty, M., & Loprinzi, C. L. (2008) · Cancer · doi:10.1002/cncr.23482 · Cited by 193
Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain
Skljarevski, V., Desaiah, D., Liu-Seifert, H., Zhang, Q., Chappell, A. S., Detke, M. J., Iyengar, S., Atkinson, J. H., & Backonja, M. (2010) · Spine · doi:10.1097/brs.0b013e3181d3cef6 · Cited by 189
Estimation of minimum clinically important difference for pain in fibromyalgia
Mease, P. J., Spaeth, M., Clauw, D. J., Arnold, L. M., Bradley, L. A., Russell, I. J., Kajdasz, D. K., Walker, D. J., & Chappell, A. S. (2011) · Arthritis Care & Research · doi:10.1002/acr.20449 · Cited by 171
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
Kajdasz, D. K., Iyengar, S., Desaiah, D., Bačkonja, M.-M., Farrar, J. T., Fishbain, D. A., Jensen, T. S., Rowbotham, M. C., Sang, C. N.-M., Ziegler, D., et al. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.002 · Cited by 141
A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy
Kaur, H., Hota, D., Bhansali, A. K., Dutta, P. R., Bansal, D., & Chakrabarti, A. (2011) · Diabetes Care · doi:10.2337/dc10-1793 · Cited by 113
Griffith, K. A., Merkies, I. S. J., Hill, E., & Cornblath, D. R. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00292.x · Cited by 110
Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.
Kautio, A.-L., Haanpää, M. L., Leminen, A., Kalso, E. A., Kautiainen, H., & Saarto, T. H. (2009) · PubMed · Cited by 106
Duloxetine for Patients with Diabetic Peripheral Neuropathic Pain: A 6-Month Open-Label Safety Study
Raskin, J., Wang, F., Pritchett, Y., & GOLDSTEIN, D. J. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00207.x · Cited by 105
Dubois, D. J., Dhawan, R., de Velde, H. J. V., Esseltine, D. L., Gupta, S. K., Viala, M., & de la Loge, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0824 · Cited by 102
Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., Ohsumi, S., Makino, H., Katsumata, N., Kuranami, M., et al. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1492-x · Cited by 101
Smith, E., Cohen, J. A., Pett, M. A., & Beck, S. L. (2010) · Cancer Nursing · doi:10.1097/ncc.0b013e3181c989a3 · Cited by 91
Self-citationBurden of chemotherapy-induced neuropathy—a cross-sectional study
Kautio, A.-L., Haanpää, M. L., Kautiainen, H., Kalso, E. A., & Saarto, T. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-1043-2 · Cited by 89
Preskorn, S., Greenblatt, D. J., Flockhart, D. A., Luo, Y., Perloff, E. S., Harmatz, J. S., Baker, B., Klick-Davis, A., Desta, Z., & Burt, T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200702000-00005 · Cited by 88
Bril, V., England, J. D., Franklin, G. M., Bačkonja, M., Cohen, J. A., Toro, D. R. D., Feldman, E. L., Iverson, D. J., Perkins, B. A., Russell, J. W., et al. (2011) · Muscle & Nerve · doi:10.1002/mus.22092 · Cited by 87
Caraci, F., Crupi, R., Drago, F., & Spina, E. (2011) · Current Drug Metabolism · doi:10.2174/138920011795713706 · Cited by 81
Frigeni, B., Piatti, M., Lanzani, F., Alberti, P., Villa, P., Zanna, C., Ceracchi, M., Ildebrando, M., & Cavaletti, G. (2011) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2011.00351.x · Cited by 80
Yang, Y.-H., Lin, J.-K., Chen, W.-S., Lin, T.-C., Yang, S.-H., Jiang, J., Chang, S., Lan, Y., Lin, C. C., Yen, C., et al. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1237-2 · Cited by 80
Marangell, L. B., Clauw, D. J., Choy, E., Wang, F., Shoemaker, S., Bradley, L., Mease, P., & Wohlreich, M. M. (2011) · Pain · doi:10.1016/j.pain.2010.05.029 · Cited by 70
Painful Diabetic Polyneuropathy: Approach to Diagnosis and Management
Spallone, V., Lacerenza, M. R., Rossi, A., Sicuteri, R., & Marchettini, P. (2011) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318243075c · Cited by 59
Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Response Profile
Pritchett, Y., McCarberg, B. H., Watkin, J. G., & Robinson, M. J. (2007) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00305.x · Cited by 58
Kuroi, K., Shimozuma, K., Ohashi, Y., Hisamatsu, K., Masuda, N., Takeuchi, A., Aranishi, T., Morita, S., Ohsumi, S., & Hausheer, F. H. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0550-x · Cited by 55
Diabetic Peripheral Neuropathy and the Management of Diabetic Peripheral Neuropathic Pain
Morales‐Vidal, S., Morgan, C., McCoyd, M., & Hornik, A. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2576 · Cited by 47
Smith, E. M. L., Bakitas, M. A., Homel, P., Piehl, M. D., Kingman, L. S., Fadul, C. E., & Bookbinder, M. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.03.017 · Cited by 35
Self-citationHall, J. A., Wang, F., Oakes, T. M. M., Utterback, B. G., Crucitti, A., & Acharya, N. V. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.484418 · Cited by 30
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers
Hua, T. C., Pan, A. X., Chan, C., et al. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02068.x · Cited by 26
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01399 · Cited by 1,113
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Metadata
- Authors
- Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., Gilman, P. B., Shapiro, C. L., & Alliance for Clinical Trials in Oncology, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-04-03
- Volume
- 309
- Issue
- 13
- Pages
- 1359
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2057662279
- Cited by
- 1,014
- References
- 63
- FWCI
- 35.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.